Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

RMOS 2024 Spring Conference Wednesday May 8, 2024 Grand Hyatt Denver Denver, CO Attendee Roster First Name Last Name Title Account Name Brenda Holcomb Manager AbbVie Inc. Janet Lucero Oncology Account Executive AbbVie Inc. Karen Wilson MN, RN, CGRN, CTTS AdventHealth Parker Anna Pugh President AGP Strategies Carla Apodaca Executive Oncology Account Specialist AstraZeneca …
BMT and Rehab CAR-T and Rehab Comprehensive Care of the Bone Marrow Transplant Patient Macy Hogan, PT, DPT Franciscan Health Objectives • To address special considerations for BMT patients to improve awareness, clinical reasoning, and standard of care when treating a BMT patient, particularly patients undergoing CAR-T therapy • To improve awareness of changes in the …
Bladder Sparing Therapies for Urothelial Cancer: A Radiation Oncolgist’s Perspective BLADDER SPARING THERAPIES FOR UROTHELIAL CANCER: A RADIATION ONCOLOGIST’S PERSPECTIVE MINNESOTA SOCIETY OF CLINICAL ONCOLOGY 2024 SPRING CONFERENCE, 04/24/2024 OUTLINE • INTRODUCTION • WORKUP, STAGING • DEFINITIVE MANAGEMENT OPTIONS • BLADDER PRESERVATION PRINCIPLES • CASES AND CONTROVERSIES …
Fecal Microbiota Transplantation in Allogeneic Stem Cell Transplantation, Acute Myeloid Leukemia, and Acute Graft-Versus-Host Disease Fecal Microbiota Transplantation in Allogeneic Stem Cell Transplantation, Acute Myeloid Leukemia, and Acute Graft-Versus-Host Disease David Kazadi, MD, PhD Fellow - Department of Medicine, Division of Hematology, Oncology, and Transplantation Minnesota …
Hitting the Target: Selecting Patients for Targeted Therapy in Metastatic Urothelial Cancer Arlene Siefker-Radtke, MD Professor Department of Genitourinary Medical Oncology Perioperative Therapy in Surgically Resectable Urothelial Carcinoma DISCLOSURE INFORMATION Arlene Siefker-Radtke, MD Advisory Boards: Abbvie, Astellas, AstraZeneca, Basilea, Bicycle Therapeutics, Bristol …
Introduction to CAR-T Therapy Introduction to CAR T-Cell Therapy Agenda • Objectives • Introduction to chimeric antigen receptor T (CAR T)–cell therapy • Current CAR T-cell products and clinical trials • CAR T-cell therapy availability • CAR T-cell treatment process • Common adverse events associated with CAR T-cell therapy • Conclusions 1 Objectives ● Review …
T1 High-grade Bladder Cancer: Contemporary Management and Outcomes HIGH RISK NMIBC: STATE OF THE ART 1 ASHISH M. KAMAT, MD, MBBS PROFESSOR OF UROLOGIC ONCOLOGY WAYNE B. DUDDLESTEN PROFESSOR OF CANCER RESEARCH DIRECTOR, BLADDER CANCER RESEARCH PRESIDENT, INTERNATIONAL BLADDER CANCER GROUP (IBCG) Ashish M. Kamat, MD 3 DEFINITION OF HIGH RISK Ashish M. Kamat, MD …
The Affordable Connectivity Program ends today, leaving 1 in 6 American households without access to high-speed internet.
Improving timely identification and referral of patients who may be eligible for chimeric antigen receptor (CAR) T-cell therapy is critical for improving outcomes for patients with hematologic malignancies. On February 7, 2024, ACCC hosted a virtual Working Summit: Advancing CAR T-Cell Therapy Care Continuity and Collaborative Patient Education to explore topics including patient and caregiver needs …
ASSOCIATION OF CANCER CARE CENTERS 1 Effective Practices for Achieving and Maintaining Better Outcomes for Patients with Acute Myeloid Leukemia INTRODUCTION This effective practice guide has been prepared to highlight opportunities and strategies for cancer pro- grams and practices to improve quality of care and outcomes for patients with acute myeloid leukemia who …
ACCC recently announced a collaboration with the Digital Medicine Society on a project to develop a risk prediction tool for cytokine release syndrome.
PowerPoint Presentation 2024 Coding Update for Oncology Topics • Reimbursement 2024 • New Code for the Office • Visit Complexity • SDOH • 2024 OIG Targets • Same Day Visit/Treatment • Incident-to • Cloning • Split/Shared Visits • Telemedicine 2024 Reimbursement • CMS Conversion Factor: 3.3% • Expected Annual Reimbursement: • Oncology: 2% …
PowerPoint Presentation Ravi Salgia, MD, PhD Professor and Chair Department of Medical Oncology and Therapeutics Research Precision Medicine in Metastatic NSCLC CITY OF HOPE Objectives  Precision Medicine at City of Hope  Lung Cancer Overview  Precision Medicine Overview  Therapeutic Strategies  Germline Testing and Strategies  Artificial Intelligence …
PowerPoint Presentation AZ Legislative Landscape TACOS Spring Conference 1 April 13, 2024 2 Vision: End cancer as we know it, for everyone. Mission: Advocate for evidence-based public policies to reduce the cancer burden for everyone. 3 6,830 Breast (Female)1 2 3 4 5 More than 42,000 Arizonans will be diagnosed with a new cancer in 2024 6 7 8 1,260 …
PowerPoint Presentation Improving Cancer Care in SW Sonoran Desert -LDCT Screening Raju Vaddepally, MD Lee Health Cancer Center, Fort Myers, FL Previous President for The Arizona Oncology Society TACOS Executive Committee for ACCC Immuno-Oncology Institute & SITC Project purpose • About 135K deaths from lung cancer in 2020 (Men slightly more than women) • Lung …
PowerPoint Presentation CITY OF HOPE 1 ASH 2023 update on AML and MDS Tibor Kovacsovics, MD City of Hope Phoenix CITY OF HOPE 2 • Research funding: Abbvie, Gilead, Glycomimetics, Novartis, Syndax • Honoraria: Rigel, Servier Disclosures CITY OF HOPE 3 Outline • AML - FLT3 mutated AML: Quizartinib - Menin inhibitors • MDS - high risk MDS: Ivosidenib …
This Is the Master Title Slide with room for the Session title text Breaking Bad News Better: Communication Skills for the Oncology Professional A B B Y F U O T O D N P , A N P - B C , A O C N P , A C H P N T H E A R I Z O N A C L I N I C A L O N C O L O G Y S O C I E T Y M E E T I N G A P R I L 1 3 , 2 0 2 4 Faculty Abby Fuoto DNP, ANP-BC, AOCNP, ACHPN Nurse …
Presentation Title Event title/location if applicable Evolving Landscape of Perioperative Therapy in Locally Advanced NSCLC TACOS 4/2024 Jiaxin (Jason) Niu, MD, PhD Adjuvant Associate Professor MD Anderson Cancer Center Co-Director of Lung Cancer Program Banner MD Anderson Cancer Center Faculty Disclosure An ineligible company is any entity whose primary business …
ASH 2023 Myelofibrosis Update Event title/location if applicable ASH 2023 Myelofibrosis Update Mark G. Faber, DO Staff Physician, Division of Hematology Banner MD Anderson Cancer Center Gilbert, AZ Banner Gateway Medical Center, Gilbert, AZ I have no relevant disclosures. What is Myelofibrosis? • Clonal myeloproliferative neoplasm (MPN) characterized by …